SEARCH:   Advanced

Blood, 15 May 2007, Vol. 109, No. 10, pp. 4164-4167. Prepublished online as a Blood First Edition Paper on January 30, 2007; DOI 10.1182/blood-2006-09-045351. This Article Full Text (PDF) Supplemental Methods and Appendix All Versions of this Article: blood-2006-09-045351v1 109/10/4164    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Wetzler, M. Articles by Larson, R. A Search for Related Content PubMed PubMed Citation Articles by Wetzler, M. Articles by Larson, R. A Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 6, 2006 Accepted January 23, 2007 Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia -- Cancer and Leukemia Group B Study 9511 Meir Wetzler*, Ben L Sanford, Joanne Kurtzberg, Divino DeOliveira, Stanley R Frankel, Bayard L Powell, Jonathan E Kolitz, Clara D Bloomfield, and Richard A Larson Leukemia Section, Roswell Park Cancer Institute, Buffalo, NY CALGB Biostatistics, Duke University Medical Center, Durham, NC Duke University Medical Center, Durham, NC Marlene and Stewart Greenebaum Cancer Center, University of Maryland Cancer Center, Baltimore, MD Wake Forest University School of Medicine, Winston-Salem, NC North Shore University Hospital, Manhasset, NY The Ohio State University Comprehensive Cancer Center, Columbus, OH University of Chicago, Chicago, IL * Corresponding author; email: meir.wetzler{at}roswellpark.org. CALGB 9511 used pegaspargase (PEG-ASP) in lieu of the native enzyme. The aim was to compare differences in overall survival (OS) and disease-free survival (DFS) between patients who did and did not achieve asparagine depletion, defined by enzyme levels >0.03 units/ml plasma for 14 consecutive days after at least one of four planned PEG-ASP administrations. Samples were available from 85 eligible patients. On univariate analyses, the 22 patients who did not achieve asparagine depletion had inferior OS [P=0.002; hazard ratio (HR)=2.37, 95% CI=1.38-4.09] and DFS (P=0.012; HR=2.21, 95% CI=1.19-4.13). After adjusting for age, performance status, leukocyte count and karyotype in a proportional hazards model, both the OS and DFS HR decreased to 1.8 (P=0.056; 95% CI=1.0-3.2 and P=0.084; 95% CI=0.9-3.6 respectively). We conclude that effective asparagine depletion with PEG-ASP is feasible as part of an intensive multi-agent therapeutic regimen in adult acute lymphoblastic leukemia and appears associated with improved outcomes. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. Stock, M. La, B. Sanford, C. D. Bloomfield, J. W. Vardiman, P. Gaynon, R. A. Larson, and J. Nachman What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies Blood, September 1, 2008; 112(5): 1646 - 1654. [Abstract] [Full Text] [PDF] A. Fielding The Treatment of Adults with Acute Lymphoblastic Leukemia Hematology, January 1, 2008; 2008(1): 381 - 389. [Abstract] [Full Text] [PDF] J. M. Rowe and A. H. Goldstone How I treat acute lymphocytic leukemia in adults Blood, October 1, 2007; 110(7): 2268 - 2275. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020